The Therapeutic Potential of α7 Nicotinic Acetylcholine Receptor (α7 nAChR) Agonists for the Treatment of the Cognitive Deficits Associated with Schizophrenia

AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation

(2015) Dominik Feuerbach et al.   BRITISH JOURNAL OF PHARMACOLOGY

Targeting Brain α7 Nicotinic Acetylcholine Receptors in Alzheimer’s Disease: Rationale and Current Status

(2014) Ana Sofía Vallés et al.   CNS DRUGS

Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication

(2014) William James Deardorff et al.   Expert Review of Neurotherapeutics

Normalizing Effects of EVP-6124, an Alpha-7 Nicotinic Partial Agonist, on Event-Related Potentials and Cognition

(2014) SHELDON H. PRESKORN et al.   Journal of Psychiatric Practice

A Randomized, Placebo-Controlled Study Investigating the Nicotinic α7 Agonist, RG3487, for Cognitive Deficits in Schizophrenia

(2014) Daniel Umbricht et al.   NEUROPSYCHOPHARMACOLOGY

AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys

(2014) Thérèse Di Paolo et al.   PARKINSONISM & RELATED DISORDERS

Preclinical characterization of a selective alpha-7 neuronal nicotinic acetylcholine receptor agonist ABT-126: A novel therapeutic agent for the treatment of cognitive impairment in Alzheimer's disease and schizophrenia

(2013) Robert Bitner et al.   Alzheimers & Dementia

P.1.j.013 Pharmacological characterisation and phase I evaluation in healthy volunteers of the nAChR agonist, AQW051

(2013) C. Lopez Lopez et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia

(2013) Jeffrey A Lieberman et al.   NEUROPSYCHOPHARMACOLOGY

Targeting alpha-7 nicotinic neurotransmission in schizophrenia: A novel agonist strategy

(2013) Stephen I. Deutsch et al.   SCHIZOPHRENIA RESEARCH

Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: A proof-of-mechanism study

(2012) Georg Winterer et al.   NEUROPHARMACOLOGY

Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: Advantages and limitations

(2011) Dustin K. Williams et al.   BIOCHEMICAL PHARMACOLOGY

α7 Nicotinic Acetylcholine Receptor as a Potential Therapeutic Target for Schizophrenia

(2011) Masatomo Ishikawa et al.   CURRENT PHARMACEUTICAL DESIGN

EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors

(2011) Jos Prickaerts et al.   NEUROPHARMACOLOGY

Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia

(2011) Carrie K Jones et al.   NEUROPSYCHOPHARMACOLOGY

Ultra-low exposure to alpha-7 nicotinic acetylcholine receptor partial agonists elicits an improvement in cognition that corresponds with an increase in alpha-7 receptor expression in rodents: implications for low dose clinical efficacy

(2011) J.L. Werkheiser et al.   NEUROSCIENCE

Immediate and Sustained Improvements in Working Memory After Selective Stimulation of α7 Nicotinic Acetylcholine Receptors

(2010) Stacy A. Castner et al.   BIOLOGICAL PSYCHIATRY

Effects of an Alpha 7-Nicotinic Agonist on Default Network Activity in Schizophrenia

(2010) Jason R. Tregellas et al.   BIOLOGICAL PSYCHIATRY

Acetylcholine-Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders

(2010) Deranda B Lester et al.   CNS Neuroscience & Therapeutics

Discovery of 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models

(2010) Christopher J. O’Donnell et al.   JOURNAL OF MEDICINAL CHEMISTRY

RG3487, a Novel Nicotinic  7 Receptor Partial Agonist, Improves Cognition and Sensorimotor Gating in Rodents

(2010) T. L. Wallace et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Drug development for Alzheimer's disease: Where are we now and where are we headed?

(2009) Marwan N. Sabbagh   American Journal Geriatric Pharmacotherapy

A reversible model of the cognitive impairment associated with schizophrenia in monkeys: Potential therapeutic effects of two nicotinic acetylcholine receptor agonists

(2009) Jerry J. Buccafusco et al.   BIOCHEMICAL PHARMACOLOGY

Selective α7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes

(2009) Simon Sydserff et al.   BIOCHEMICAL PHARMACOLOGY

R3487/MEM 3454, a novel nicotinic alpha 7 receptor partial agonist, improves attention and working memory performance in cynomolgus macaques

(2009) T.L. Wallace et al.   BIOCHEMICAL PHARMACOLOGY

TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia

(2009) T.A. Hauser et al.   BIOCHEMICAL PHARMACOLOGY

Nicotinic acetylcholine receptors: an overview on drug discovery

(2009) Dieter D'hoedt et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

In Vitro Pharmacological Characterization of a Novel Allosteric Modulator of  7 Neuronal Acetylcholine Receptor, 4-(5-(4-Chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), Exhibiting Unique Pharmacological Profile

(2009) J. Malysz et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Schizophrenia

(2009) Jim van Os et al.   LANCET

Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system

(2009) Antoine Taly et al.   NATURE REVIEWS DRUG DISCOVERY

Pro-Cognitive and Antipsychotic Efficacy of the α7 Nicotinic Partial Agonist SSR180711 in Pharmacological and Neurodevelopmental Latent Inhibition Models of Schizophrenia

(2009) Segev Barak et al.   NEUROPSYCHOPHARMACOLOGY

Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia

(2008) Robert Freedman et al.   AMERICAN JOURNAL OF PSYCHIATRY

Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the α7 nicotinic acetylcholine receptor: In vitro and in vivo activity

(2008) Brad A. Acker et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Preclinical Characterization of A-582941: A Novel α7 Neuronal Nicotinic Receptor Agonist with Broad Spectrum Cognition-Enhancing Properties

(2008) Karin R. Tietje et al.   CNS Neuroscience & Therapeutics

Effect of R3487/MEM3454, a novel nicotinic α7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats

(2008) Amir H. Rezvani et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY